What is HC Wainwright’s Estimate for ALLO FY2025 Earnings?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at HC Wainwright upped their FY2025 earnings per share estimates for Allogene Therapeutics in a note issued to investors on Monday, November 10th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.93) per share for the year, up from their previous estimate of ($1.06). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q4 2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($1.01) EPS.

Other research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Allogene Therapeutics in a research report on Friday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Wednesday, October 8th. Wall Street Zen downgraded Allogene Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 12th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a research report on Monday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Allogene Therapeutics Trading Down 2.4%

NASDAQ:ALLO opened at $1.20 on Wednesday. The firm has a fifty day simple moving average of $1.22 and a 200 day simple moving average of $1.23. Allogene Therapeutics has a 1-year low of $0.86 and a 1-year high of $3.78. The stock has a market capitalization of $269.68 million, a PE ratio of -1.22 and a beta of 0.42.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quadrature Capital Ltd raised its position in shares of Allogene Therapeutics by 29.6% during the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company’s stock worth $50,000 after acquiring an additional 10,059 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Allogene Therapeutics by 4.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 264,065 shares of the company’s stock valued at $386,000 after purchasing an additional 10,489 shares during the period. Brighton Jones LLC raised its holdings in Allogene Therapeutics by 81.6% during the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after purchasing an additional 11,311 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of Allogene Therapeutics by 17.8% in the 1st quarter. Hsbc Holdings PLC now owns 81,435 shares of the company’s stock worth $115,000 after purchasing an additional 12,280 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Allogene Therapeutics by 19.6% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 85,720 shares of the company’s stock valued at $106,000 after purchasing an additional 14,032 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Allogene Therapeutics

In other news, CFO Geoffrey M. Parker sold 36,744 shares of the company’s stock in a transaction that occurred on Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total value of $46,297.44. Following the transaction, the chief financial officer owned 1,276,796 shares of the company’s stock, valued at approximately $1,608,762.96. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.20% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).